enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2019
At a glance
- Drugs ACP 001 (Primary)
- Indications Somatotropin deficiency
- Focus Adverse reactions; Registrational
- Acronyms enliGHten
- Sponsors Ascendis Pharma
- 08 Jan 2019 Planned number of patients changed from 400 to 300.
- 31 Aug 2018 Biomarkers information updated
- 20 Dec 2017 Status changed from not yet recruiting to recruiting.